Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease
Maria Rosario(Millennium Engineering and Integration (United States)), Irving H. Fox(Takeda (United States)), Jean‐Frédéric Colombel(Mount Sinai Hospital), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), William J. Sandborn(University of San Diego), Silvio Danese(IRCCS Ospedale San Raffaele), Brian G. Feagan(Western University), Serap Sankoh(Millennium Engineering and Integration (United States)), Jonathan French(Metrum Research Group (United States)), Michael Smyth, Nathanael L. Dirks(Metrum Research Group (United States)), Miguel Sans(Hospital Quirón Teknon), Asit Parikh, Huyuan Yang(Takeda (United States)), Walter Reinisch(Medical University of Vienna)
Cited by 161
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k